A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers

被引：0
作者：
Rui Chen
Hongyun Wang
Wen Zhong
Salvatore Chessari
Corinna Lanzarotti
Alberto Bernareggi
Pei Hu
机构：
[1] Peking Union Medical College Hospital,Clinical Pharmacology Research Center
[2] Helsinn Healthcare SA,Scientific Operations Division
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Antiemetic; NEPA; Netupitant; Palonosetron; Pharmacokinetics; China;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：387 / 396
页数：9
相关论文
共 50 条
  • [1] A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
    Chen, Rui
    Wang, Hongyun
    Zhong, Wen
    Chessari, Salvatore
    Lanzarotti, Corinna
    Bernareggi, Alberto
    Hu, Pei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 387 - 396
  • [2] Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients
    Aapro, Matti
    Jordan, Karin
    Gralla, Richard J.
    Rizzi, Giada
    Rossi, Giorgia
    Palmas, Marco
    Alyasova, Anna V.
    Lisyanskaya, Alla S.
    Bosnjak, Snezana M.
    Hesketh, Paul J.
    JOURNAL OF GERIATRIC ONCOLOGY, 2017, 8 (01) : 56 - 63
  • [3] Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting
    Lorusso, Vito
    Karthaus, Meinolf
    Aapro, Matti
    FUTURE ONCOLOGY, 2015, 11 (04) : 565 - 577
  • [4] Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting
    Gilmore, James
    Bernareggi, Alberto
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04) : 472 - 487
  • [5] Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy
    Bosnjak, Snezana M.
    Stamatovic, Ljiljana
    Borroni, Maria Elisa
    Rizzi, Giada
    Jordan, Karin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (06) : 1153 - 1161
  • [6] Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives
    Calcagnile, Selma
    Lanzarotti, Corinna
    Rossi, Giorgia
    Henriksson, Anders
    Kammerer, Klaus Peter
    Timmer, Wolfgang
    SUPPORTIVE CARE IN CANCER, 2013, 21 (10) : 2879 - 2887
  • [7] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    Matti Aapro
    Meinolf Karthaus
    Lee Schwartzberg
    Igor Bondarenko
    Tomasz Sarosiek
    Cristina Oprean
    Servando Cardona-Huerta
    Vincent Hansen
    Giorgia Rossi
    Giada Rizzi
    Maria Elisa Borroni
    Hope Rugo
    Supportive Care in Cancer, 2017, 25 : 1127 - 1135
  • [8] Evaluation of the Effect of Food and Age on the Pharmacokinetics of Oral Netupitant and Palonosetron in Healthy Subjects: A Randomized, Open-Label, Crossover Phase 1 Study
    Calcagnile, Selma
    Lanzarotti, Corinna
    Gutacker, Michaela
    Jakob-Rodamer, Verena
    Kammerer, Klaus Peter
    Timmer, Wolfgang
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (05): : 377 - 386
  • [9] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    Aapro, Matti
    Karthaus, Meinolf
    Schwartzberg, Lee
    Bondarenko, Igor
    Sarosiek, Tomasz
    Oprean, Cristina
    Cardona-Huerta, Servando
    Hansen, Vincent
    Rossi, Giorgia
    Rizzi, Giada
    Borroni, Maria Elisa
    Rugo, Hope
    SUPPORTIVE CARE IN CANCER, 2017, 25 (04) : 1127 - 1135
  • [10] Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives
    Selma Calcagnile
    Corinna Lanzarotti
    Giorgia Rossi
    Anders Henriksson
    Klaus Peter Kammerer
    Wolfgang Timmer
    Supportive Care in Cancer, 2013, 21 : 2879 - 2887
12345